Covering Wall Street analysts are anticipating Cytokinetics, Incorporated (NASDAQ:CYTK) to post quarterly earnings per share of $-0.27 on a consensus basis. This consensus number includes analysts polled by Zacks Research. The estimate might differ from other data providers that compile consensus estimates. The company most recently reported quarterly EPS of $-0.29 for the period ending on 2016-06-30. This number ended up $-0.01 off the Zacks consensus estimate resulting in a surprise factor of-3.57%.
In taking a look at where analysts believe Cytokinetics, Incorporated (NASDAQ:CYTK) is headed, the covering brokerages have a one year target price of $20.6 on the shares. This is based on the 5 analysts polled by Zacks Research. The analyst with the most aggressive viewpoint sees the stock heading towards $24 within the next 12 months while the most bearish sees the shares going to $16 in that same timeframe. The most recent analyst revision occurred on 2016-09-02. Depending on the brokerage firm, analysts on the sell-side use alternate terminology to describe their Buy/Sell recommendations.
Retail investors not familiar with a particular firms reports could find the recommendations difficult to understand. As a result, Zacks offers an analyst brokerage rating (ABR) which simplifies the recommendations into a 1 to 5 sliding scale where one represents a Strong Buy and 5 indicates a Strong Sell. Cytokinetics, Incorporated (NASDAQ:CYTK) currently has an ABR 1.2. This is the average recommendation based on the 5 analysts polled.
Please note that the data derived in this report is from Zacks Research. This is not a recommendation to Buy or Sell shares of Cytokinetics, Incorporated. The author of this article does not hold any position in the company. Investors should conduct their own thorough research before buying or selling equities.